Tidewave is building a platform to turn a patient’s tumor biopsy into an active input for personalized treatment, biological profiling, and learning over time.
Today, a tumor biopsy is primarily used to diagnose and characterize cancer. Tidewave is developing a different model: use that same tumor material as an active input for treatment, biological profiling, and longitudinal monitoring.
Tidewave is designed to connect steps that are usually separated : preparing tumor material, personalizing treatment, and learning from what happens next.
Start with the patient’s tumor.
Turn the sample into a usable biological input.
Let the tumor guide the treatment.
Connect treatment with what happens next.
The same biopsy-centered workflow can support both personalized treatment and ongoing biological insight, rather than operating as separate systems.
Tidewave Bio Cells-1 (TBC-1) is Tidewave’s first therapeutic program. It is prepared in advance and personalized with material from the patient’s tumor, with the goal of helping the immune system recognize a broader picture of that patient’s cancer
The platform can also support molecular and immune profiling, tissue and blood-based analysis, and longitudinal monitoring to follow how the disease responds and changes.
The first biopsy tells us where the patient begins. What happens afterward may tell us just as much. By connecting the original tumor with later tissue, blood, immune readouts, and clinical outcomes, Tidewave is designed to create a growing picture of how the disease responds.
Not everything in precision oncology needs to happen in the same place. Tidewave is designed to connect hospital sites, the Tidewave operating layer, and specialized partners
